REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
13

Argireline — Before and After

Darcy Falk·28 days ago
Sharing my Argireline before-and-after experience. Not posting photos because this is about objective data, not visual impressions. Baseline bloodwork vs. 12-week bloodwork showed improvements in several markers. Inflammatory markers trended down, fasting glucose improved slightly, and lipid panel was essentially unchanged. Body composition: lost about 3 lbs of fat and gained roughly 1.5 lbs of lean mass based on DEXA. These are modest numbers but they came without any change to my diet or training program, which had been stable for months before starting. Subjective improvements: significantly better sleep, faster recovery, improved joint comfort, and a general sense of feeling healthier. These are soft metrics but they matter for quality of life. What I wish I had done differently: more comprehensive baseline testing. I got basic bloodwork but wish I had also done inflammatory panels, hormone panels, and a baseline DEXA. Having that data would have made the results more meaningful. Would recommend Argireline to someone with realistic expectations. It is not going to change your life overnight but it can meaningfully improve several health markers over a proper protocol duration.

Comments (5)

Crew BaldwinDEMO·28 days ago

Been following this thread with interest. My Argireline experience was similar in most ways, though I found the recovery benefits took a bit longer to kick in for me — closer to week 5-6 rather than 3-4. Individual variation is real and I think people need to be patient before concluding something is or is not working.

3
Crew CameronDEMO·27 days ago

Solid protocol. One suggestion: consider adding HRV tracking if you are not already. It has been the most objective and responsive metric for me during my Argireline protocol. Changes in HRV preceded subjective improvements by about a week, which gave me early confidence the protocol was working.

4
Jude FosterDEMO·27 days ago

Your point about consistency being more important than optimization really resonates. I wasted weeks early in my Argireline journey tweaking doses and timing when I should have just picked a reasonable protocol and stuck with it. The best results came when I stopped overthinking and just stayed consistent.

5
Reed FreemanDEMO·27 days ago

This is a great discussion about Argireline. I want to add that I found morning dosing on an empty stomach gave me noticeably better results than evening dosing. Tried both for 4 weeks each. The difference was subtle but consistent across my tracking metrics.

2
Lake AdamsDEMO·27 days ago

Thanks for sharing the science behind Argireline. I think the mechanism explanation really helps people understand why patience is necessary with these protocols. It is not like taking a painkiller where you feel effects in 30 minutes — you are initiating biological programs that take weeks to fully manifest.

3

Sign in to comment.